Espero BioPharma CEO and BioFlorida Member Quang Pham selected as EY Entrepreneur Of The Year® 2017 Award finalist in Florida

JACKSONVILLE, Fla, May 4, 2017 – EY today announced that Quang Pham, Chief Executive Officer of Espero BioPharma, Inc., is a finalist for the Entrepreneur Of The Year® 2017 Award in Florida. The awards program, which is celebrating its 31st year, recognizes entrepreneurs who are excelling in areas such as innovation, financial performance and personal […]

Read more

Espero Pharmaceuticals and Armetheon to Merge and Create a 
Premier Cardiovascular Focused Biopharmaceutical Company

JACKSONVILLE, Fla. and MENLO PARK, Calif. (March 30, 2017) – Espero Pharmaceuticals, Inc., a privately held, commercial-stage cardiovascular pharmaceutical company, and Armetheon, Inc., a privately held, late-clinical stage pharmaceutical company developing innovative novel drugs addressing major unmet needs in cardiovascular diseases, today announced their plans to merge. Upon completion of the merger, which is expected […]

Read more

Espero Acquires DURLAZA® (aspirin) Extended Release Capsules 
for Secondary Prevention of Stroke and Acute Cardiac Events

JACKSONVILLE, Fla. (February 7, 2017) – Espero Pharmaceuticals, Inc., a commercial-stage cardiovascular pharmaceutical company, today announced that the company has acquired the global rights to DURLAZA® (aspirin) Extended Release Capsules.Company officials will provide an update on February 13, 2017 at the BIO CEO & Investor Conference held at the Waldorf Astoria New York. DURLAZA is […]

Read more

GONITRO™ to Participate in First-of-its-Kind 
Comparative Effectiveness ISCHEMIA Clinical Trial Sponsored by the National Institutes of Health

JACKSONVILLE, Fla. (Jan. 19, 2017) – Espero Pharmaceuticals, Inc., a commercial-stage cardiovascular pharmaceutical company, will donate GONITRO™ (nitroglycerin sublingual powder) to the ongoing International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) clinical trial and to the ISCHEMIA-Chronic Kidney Disease (CKD) ancillary trial. The company’s executives provided an update during last week’s […]

Read more

Espero Pharmaceuticals to Present at 9th Annual Biotech Showcase

JACKSONVILLE, Fla. (December 20, 2016) – Espero Pharmaceuticals, Inc., a commercial-stage cardiovascular pharmaceutical company, announced today that the company has been invited to present at the 9th Annual Biotech Showcase in San Francisco from January 9-11, 2017. Quang Pham, Chief Executive Officer, and Jeff Cole, President and Chief Financial Officer, will provide an update on […]

Read more

Espero Pharmaceuticals CEO, Quang Pham, is Honored by BioFlorida with its Entrepreneur of the Year Award

The Entrepreneur of the Year Award recognizes an entrepreneur who has made extraordinary contributions to the growth of life sciences in the leadership of a company or institution. The 2016 Entrepreneur of the Year Award was presented to Quang Pham, Founder and CEO of Espero Pharmaceuticals, a privately held, cardiovascular pharmaceutical company focused on compounds […]

Read more

Jacksonville Business Journal honors Espero Founder & CEO Quang Pham as a Jacksonville Veteran of Influence

The Veterans of Influence award acknowledges those who have given back to the community by leading companies, organizing philanthropic projects and using the skills and talents they developed in uniform to make their mark on the First Coast. These honorees make a difference and help set the standard for the rest of Jacksonville’s business community. […]

Read more

Espero Pharmaceuticals Announces the Availability of FDA-Approved GONITRO™ (Nitroglycerin) Sublingual Powder in the U.S.

New Short-Acting Nitrate Powder Now Available in Single Dose Packets 
for Acute Relief of an Angina Pectoris Attack JACKSONVILLE, Fla. (Sept. 27, 2016) – Espero Pharmaceuticals Inc., a privately held specialty pharmaceutical company, today announced the commercial availability of GONITRO™ (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris due […]

Read more

Espero Pharmaceuticals Selects DDB Health and Alamo Pharma Services as Partners for the Launch of GONITRO™ (Nitroglycerin) Sublingual Powder

Available in Single Dose Packets, GONITRO™ is Approved For 
Acute Relief of an Angina Pectoris Attack Due to Coronary Artery Disease JACKSONVILLE, Fla. (August 30, 2016) – Espero Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that DDB Health, an Omnicom Health Group company, as its agency of record for GONITRO™. Omnicom is […]

Read more

1 2